Brief: H Lundbeck Explores New Area In Neurohormonal Dysfunctions
June 19 (Reuters) - H Lundbeck A/S HLUNb.CO :
* EXPLORES NEW AREA IN NEUROHORMONAL DYSFUNCTIONS BY
INITIATING
PHASE II TRIAL USING LU AG13909 AS POTENTIAL TREATMENT FOR
CUSHING'S DISEASE
Source text for Eikon: ID:nWkr2s4XZp
Further company coverage: HLUNb.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options